US HB2038 | 2019-2020 | 116th Congress

Status

Spectrum: Partisan Bill (Republican 3-0)
Status: Introduced on April 2 2019 - 25% progression, died in committee
Action: 2019-05-15 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Pending: House Subcommittee on Antitrust, Commercial, and Administrative Law Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Authorizes health insurance issuers to jointly negotiate the prices for prescription drugs with the manufacturers of such drugs.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019

Sponsors


History

DateChamberAction
2019-05-15HouseReferred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
2019-04-02HouseReferred to the House Committee on the Judiciary.
2019-04-02HouseIntroduced in House

Same As/Similar To

SB4796 (Related) 2020-10-05 - Read twice and referred to the Committee on Finance.
HB8527 (Related) 2020-10-02 - Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, the Judiciary, Oversight and Reform, House Administration, Rules, the Budget, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Subjects


US Congress State Sources


Bill Comments

feedback